Oragenics (OGEN) Competitors $3.65 -0.06 (-1.62%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.78 +0.13 (+3.42%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock OGEN vs. LIPO, BCTX, AYTU, NERV, TRIB, ATHA, PHIO, BCDA, AIMD, and BGXXShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Lipella Pharmaceuticals (LIPO), BriaCell Therapeutics (BCTX), Aytu BioPharma (AYTU), Minerva Neurosciences (NERV), Trinity Biotech (TRIB), Athira Pharma (ATHA), Phio Pharmaceuticals (PHIO), BioCardia (BCDA), Ainos (AIMD), and Bright Green (BGXX). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. Its Competitors Lipella Pharmaceuticals BriaCell Therapeutics Aytu BioPharma Minerva Neurosciences Trinity Biotech Athira Pharma Phio Pharmaceuticals BioCardia Ainos Bright Green Lipella Pharmaceuticals (NASDAQ:LIPO) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Is LIPO or OGEN more profitable? Oragenics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% Oragenics N/A -2,087.95%-486.56% Does the MarketBeat Community favor LIPO or OGEN? Lipella Pharmaceuticals received 1 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformLipella PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesOragenicsOutperform VotesNo VotesUnderperform Votes55100.00% Which has better valuation & earnings, LIPO or OGEN? Lipella Pharmaceuticals has higher revenue and earnings than Oragenics. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$540K13.66-$5.02M-$4.08-0.40Oragenics$40K65.24-$20.66M-$33.63-0.11 Do insiders & institutionals believe in LIPO or OGEN? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 10.1% of Oragenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, LIPO or OGEN? Lipella Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Does the media favor LIPO or OGEN? In the previous week, Lipella Pharmaceuticals had 3 more articles in the media than Oragenics. MarketBeat recorded 3 mentions for Lipella Pharmaceuticals and 0 mentions for Oragenics. Lipella Pharmaceuticals' average media sentiment score of 0.50 beat Oragenics' score of 0.00 indicating that Lipella Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Lipella Pharmaceuticals Neutral Oragenics Neutral SummaryLipella Pharmaceuticals beats Oragenics on 12 of the 15 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.61M$755.72M$5.21B$19.67BDividend YieldN/A4.84%5.38%3.80%P/E Ratio-0.521.1225.6226.97Price / Sales65.24223.32396.5939.73Price / CashN/A23.4435.5221.33Price / Book5.986.177.974.38Net Income-$20.66M-$26.36M$3.15B$986.75M7 Day Performance-16.28%-0.01%1.25%0.07%1 Month Performance-36.63%10.51%4.88%3.20%1 Year Performance-91.55%5.22%40.30%10.12% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenics0.2939 of 5 stars$3.65-1.6%N/A-91.6%$2.61M$40K-0.525Gap UpLIPOLipella Pharmaceuticals1.4771 of 5 stars$2.94+2.1%N/A-68.0%$13.13M$536.36K-0.694News CoverageGap DownBCTXBriaCell Therapeutics2.5163 of 5 stars$3.43-1.0%$32.00+831.9%-84.3%$12.70MN/A-0.268Earnings ReportAYTUAytu BioPharma1.2869 of 5 stars$2.02+0.0%N/A-28.1%$12.60M$81.66M-1.41160NERVMinerva Neurosciences3.4575 of 5 stars$1.80flat$5.00+177.8%-47.8%$12.59MN/A-4.099News CoverageTRIBTrinity Biotech1.1329 of 5 stars$0.70+5.3%N/A-77.3%$12.55M$61.56M-0.31480ATHAAthira Pharma2.3183 of 5 stars$0.32-6.8%$13.83+4,209.4%-86.8%$12.53MN/A-0.1140PHIOPhio Pharmaceuticals3.093 of 5 stars$2.55+3.0%$14.00+450.1%-64.6%$12.48MN/A-0.2410BCDABioCardia3.5282 of 5 stars$2.29-0.2%$25.00+994.1%-38.5%$11.83M$3K-0.5540Positive NewsAIMDAinos0.6491 of 5 stars$0.57-4.0%N/A-41.7%$11.79M$106.21K-0.4440Gap DownBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap Down Related Companies and Tools Related Companies Lipella Pharmaceuticals Competitors BriaCell Therapeutics Competitors Aytu BioPharma Competitors Minerva Neurosciences Competitors Trinity Biotech Competitors Athira Pharma Competitors Phio Pharmaceuticals Competitors BioCardia Competitors Ainos Competitors Bright Green Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
